Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer.

Cancer genomics & proteomics - 1 Jan 2000

Chevallier Mathieu, Tsantoulis Petros, Addeo Alfredo, Friedlaender Alex

Abstract excerpt

BACKGROUND/AIM: Non-small cell lung cancer (NSCLC) patients with activating somatic mutations in the epidermal growth factor receptor (EGFR) have better outcomes with tyrosine kinase inhibitors (TKIs) than with chemotherapy. However, even with the most effective therapies, not all patients respond. The presence of concurrent pathogenic mutations could play a role in resistance. The objective of this study was to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Class I Phosphatidylinositol 3-Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Progression-Free Survival

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins p21(ras)

Share to PTEN Phosphohydrolase

Source

Open in PubMed Open full text

Identifiers

PMID: 32859638
DOI: 10.21873/cgp.20216
PMCID: PMC7472449

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Influence of Concurrent Mutations on Overall Survival in EGFR-mutated Non-small Cell Lung Cancer.PMID 32859638Read ↗

The significance of co-mutations in EGFR-mutated non-small cell lung cancer: Optimizing the efficacy of targeted therapies?Semantic proximity Read ↗

Differential Responses to Targeted Therapies in Non-Small Cell Lung Cancer: A Comparative Analysis of Outcomes in Patients with Single EGFR Mutation and Concurrent Gene AlterationsSemantic proximity Read ↗

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A ReviewSemantic proximity Read ↗

Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohortsSemantic proximity Read ↗

Concomitant driver mutations in advanced EGFR -mutated non-small-cell lung cancer and their impact on erlotinib treatmentSemantic proximity Read ↗

Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.Semantic proximity Read ↗

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) PatientsSemantic proximity Read ↗

Real-World Efficacy of First- and Second-Generation EGFR TKIs in NSCLC with EGFR Co-mutations: A Vietnamese Cohort StudySemantic proximity Read ↗

EGFR-Co-Mutated Advanced NSCLC and Response to EGFR Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

Concurrent gene alterations with EGFR mutation and treatment efficacy of EGFR-TKIs in Chinese patients with non-small cell lung cancer.Semantic proximity Read ↗

Real-world efficacy of first- and second-generation EGFR TKIs in NSCLC with EGFR co-mutations: a Vietnamese cohort study.Semantic proximity Read ↗

Anlotinib plus icotinib as a potential treatment option for EGFR-mutated advanced non-squamous non-small cell lung cancer with concurrent mutations: final analysis of the prospective phase 2, multicenter ALTER-L004 study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.